Ajooni Biotech Limited Approves Increase in Authorized Share Capital at Annual General Meeting
Ajooni Biotech Limited has approved an increase in its Authorized Share Capital and made amendments to the Capital Clause of its Memorandum of Association. The decision was formalized by the company's members during the 16th Annual General Meeting (AGM).The meeting, which was held through video conferencing, saw special resolution approval for the capital restructuring on July 29, 2026. Following this approval, the voting results and scrutinizer report were declared on July 31, 2026.
As a result of the amendment, the Authorized Share Capital of Ajooni Biotech Limited has been set at Rs. 70,00,00,000 (Rupees Seventy Crores Only). This capital is divided into 35,00,00,000 Equity Shares, each having a face value of Rs. 2 (Rupees Two Only).
The key details of the revised Authorized Share Capital are presented below:
| Parameter | Details |
|---|---|
| Company Name | Ajooni Biotech Limited |
| New Authorized Share Capital | Rs. 70,00,00,000/- |
| Total Equity Shares | 35,00,00,000 |
| Face Value per Share | Rs. 2/- |
The approval and subsequent reporting of these decisions solidify the structure of the company's share capital as detailed in the amended Clause V of the Memorandum of Association.
AJOONI Stock Price Movement
Shares of Ajooni Biotech Limited today slipped by 0.50%, closing at ₹4.00 after settling down by ₹0.02. The stock recorded a trading volume of 97,601 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.